Seres Therapeutics vs Shattuck Labs
MCRB and STTK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MCRB and STTK compare
Shattuck Labs is the larger company, worth 34 times as much as Seres Therapeutics ($507M against $14.9M).
Seres Therapeutics grew revenue faster over the last twelve months (505% versus −100% for Shattuck Labs).
Shattuck Labs scores higher on the StockData Score (8 against 7 for Seres Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MCRB | STTK |
|---|---|---|
| Size and price | ||
| Market cap | $14.9M | $507M |
| Share price | $1.50 | $5.05 |
| Change, 1 year | −89.3% | 167% |
| Change, 5 years | −99.2% | −46.3% |
| Beta (5Y) | 1.02 | 1.63 |
| Employees | 66 | 40 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.0× | – |
| P/B | 0.7× (better) | 2.6× |
| FCF yield | −429% | – |
| Growth | ||
| Revenue growth (TTM) | 505% (better) | −100% |
| Revenue growth, 5Y average | −52.7% | −36.8% (better) |
| Net income growth (TTM) | −970% | – |
| EPS growth (TTM) | −931% | – |
| Profitability | ||
| Operating margin | −3657% | – |
| Net margin | −2210% | – |
| FCF margin | −3010% | – |
| Return on equity | −144% | −47.2% (better) |
| Return on invested capital | – | −2531% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.65 | 15.80 (better) |
| Altman Z-score | −24.75 | 17.92 (better) |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −19.9% |
| Shareholder yield | 0.00% (better) | −19.9% |
| Ownership | ||
| Held by institutions | 22.9% | 83.5% |
| Held by insiders | 2.3% | 24.1% |
| Insider net buying, 12 months | −$10.0K (better) | −$342K |
| Short interest, % of float | 3.5% | 14.1% |
Go deeper
- MCRB stock overview
- MCRB income statement
- MCRB valuation and score
- STTK stock overview
- STTK income statement
- STTK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.